Novartis Pharmaceuticals – Heart Failure With Reduced Ejection Fraction (HF-rEF)

Access Program Information

Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide
access to life-saving treatment with LCZ696 for patients that were not previously exposed to
LCZ696 but have no other option to receive LCZ696 in their country prior to market
authorization OR commercial availability, based on local regulatory and legal requirements.

Rare Disease: